On February 13, Chief Market Strategist at Carson Group Ryan Detrick and CEO of MCC Global Enterprises Michelle Caruso-Cabrera joined CNBC to discuss rising geopolitical tensions, tariff shifts, and whether tech weakness is a buying opportunity. Detrick shifted the focus to market performance and noted that it is Friday the 13th ahead of the President’s Day long weekend.
Despite the geopolitical tension, he highlighted that the S&P 500 and the Dow have both risen for nine consecutive months on a total return basis. However, he warned that the second half of February is a period where the market could see a 5% dip due to high optimism and put-to-call ratios. Despite this potential short-term slip, he maintained that the bull market remains intact with solid fundamentals.
Caruso-Cabrera added that the market has shifted to a state of indiscriminate selling. She critiqued the current Netflix or Blockbuster mentality and argued that not every AI company will destroy every legacy company. Detrick agreed and pointed out that short interest in the XLK (Tech ETF) has soared to its highest level in years. He revealed that the Carson Group has actually added to tech and software positions and noted that software valuations are at their cheapest since 2013, viewing it as a buying opportunity.
That being said, we’re here with a list of the 10 best growth stocks to buy for the next 20 years.
Our Methodology
We used the Finviz stock screener to find growth stocks with at least 20% EPS growth in the past 5 years and at least 20% expected EPS growth for the next year. We then selected 10 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2025.
Note: All data was sourced on February 18.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10 Best Growth Stocks to Buy for the Next 20 Years
10. Akebia Therapeutics Inc. (NASDAQ:AKBA)
Number of Hedge Fund Holders: 21
Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the best growth stocks to buy for the next 20 years. On February 6, Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Akebia to $4 from $6 and kept an Overweight rating. This adjustment was made as part of a broader review of commercial-stage companies, with the firm updating estimates and price targets following several year-end preliminary reports and ahead of official Q4 2025 results.
In Q3, Akebia Therapeutics Inc. (NASDAQ:AKBA) reported total revenue of $58.8 million with a net income of $540,000, successfully pivoting from a $20 million net loss in Q3 2024. While the launch of its dialysis drug Vafseo saw lower-than-expected revenue of $14.3 million due to operational and adherence hurdles, the company expanded its patient access to 70,000 and reached a milestone of over 700 active prescribers.
Despite an anticipated temporary revenue dip in Q4 due to inventory adjustments at US Renal Care, management projects growth to resume in Q1 2026. The company remains focused on its 2026 pipeline outlook, including the initiation of a Phase 2 rare kidney disease study, while maintaining that its current cash reserves are sufficient to fund its path toward sustained profitability.
Akebia Therapeutics Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes therapeutics for patients with kidney diseases.
9. LiveRamp Holdings Inc. (NYSE:RAMP)
Number of Hedge Fund Holders: 27
LiveRamp Holdings Inc. (NYSE:RAMP) is one of the best growth stocks to buy for the next 20 years. On February 6, DA Davidson lowered its price target on LiveRamp to $35 from $45 with a Buy rating. Although the company exceeded top and bottom-line expectations in FQ3 2026, management left its fiscal year 2026 guidance unchanged. The analyst attributed this cautious outlook to the timing of specific project-based expenses shifting into FQ4 and marketplace growth that came in softer than previously anticipated.
In its FQ3 earnings report posted a day prior, LiveRamp Holdings Inc. (NYSE:RAMP) announced revenue growth of 9% year-over-year to $212 million. Management highlighted a significant strategic partnership with Publicis and the expansion of its Data Marketplace to include AI models and agents, which they believe positions the firm for double-digit growth in fiscal year 2027.
While the company is successfully growing its high-value million-dollar-plus accounts, subscription net retention compressed to 101%, and gross margins are expected to dip slightly as backend platform upgrades conclude. Looking ahead to FQ4, LiveRamp projected a sequential increase in operating expenses of $15 million due to seasonal events and compensation adjustments, while providing a full-year revenue guidance range of $810 million to $814 million.
LiveRamp Holdings Inc. (NYSE:RAMP) is a technology company that operates a data collaboration platform in the US, Europe, the Asia-Pacific, and internationally.
8. Cellebrite DI Ltd. (NASDAQ:CLBT)
Number of Hedge Fund Holders: 31
Cellebrite DI Ltd. (NASDAQ:CLBT) is one of the best growth stocks to buy for the next 20 years. On February 12, following the company’s solid Q4 2025 results, TD Cowen lowered its price target on Cellebrite to $23 from $25 and maintained a Buy rating. The firm cited market contraction as the reason for the reduction, despite the company reporting 21% growth in both annual recurring revenue and subscription revenue alongside a positive outlook for 2026.
On the same day, Needham also lowered its price target on Cellebrite DI Ltd. (NASDAQ:CLBT) to $18 from $24 while maintaining a Buy rating. This announcement was made following the company’s strong Q4 2025 earnings performance.
The company’s total ARR (Annual Recurring Revenue) grew 21% year-over-year to $481 million, supported by the acquisition of Corellium and high adoption of its Inseyets platform. The firm noted that management’s 2026 outlook, which projects ARR reaching up to $573 million, aligns with previous goals for an ARR re-acceleration, signaling high conviction in the company’s growth trajectory despite broader market valuation adjustments.
Cellebrite DI Ltd. (NASDAQ:CLBT) develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.
7. Upstart Holdings Inc. (NASDAQ:UPST)
Number of Hedge Fund Holders: 37
Upstart Holdings Inc. (NASDAQ:UPST) is one of the best growth stocks to buy for the next 20 years. On February 17, following the company’s Q4 2025 earnings report, Compass Point analyst Giuliano Bologna upgraded Upstart from Sell to Neutral and raised the price target to $30 from $20. Bologna noted that while the company’s 2028 outlook is ambitious, successful execution would make the shares less expensive and provide a potential case for upside.
On February 13, Goldman Sachs upgraded Upstart to Neutral from Sell and set a $35 price target, down from its previous target of $44. The firm noted that its earlier bearish thesis, which was centered on potential margin and take rate compression from new products, has now materialized and is better understood by the market. Given that the stock has plummeted 60% since the firm first issued the Sell rating last July, Goldman Sachs believes that the risk-reward profile is now more balanced.
Additionally, Bank of America lowered its price target on Upstart Holdings Inc. (NASDAQ:UPST) to $60 from $71 and kept a Neutral rating. This adjustment followed a decent Q4 2025 report and an unexpectedly strong 2026 revenue forecast of $1.4 billion, well above the $1.27 billion consensus.
Upstart Holdings Inc. (NASDAQ:UPST), together with its subsidiaries, operates a cloud-based AI lending platform in the US. The company has three segments: Personal Lending, Auto Lending, and Other.
6. Klaviyo Inc. (NYSE:KVYO)
Number of Hedge Fund Holders: 48
Klaviyo Inc. (NYSE:KVYO) is one of the best growth stocks to buy for the next 20 years. On February 11, Needham analyst Scott Berg lowered the firm’s price target on Klaviyo to $30 from $45 but maintained a Buy rating following a very strong Q4 2025 earnings report. The company achieved high-end revenue outperformance fueled by robust sales and customer expansion during the holiday season. The analyst highlighted that despite the price target reduction, Klaviyo’s core metrics remain strong, reflecting successful execution in both its mid-market and enterprise segments.
Stifel lowered its price target on Klaviyo to $35 from $40 with a Buy rating. The firm noted that the company delivered a strong beat and raise for Q4, which should help counter recent negative market sentiment. However, the firm reduced the target to account for multiple compression despite the company’s robust financial performance and raised 2026 outlook.
Furthermore, Canaccord lowered its price target on Klaviyo Inc. (NYSE:KVYO) on the same day to $32 from $45 but maintained a Buy rating, suggesting that investor fears regarding AI disruption are overshadowing the company’s strong performance. Despite market concerns, the firm noted that Klaviyo continues to execute effectively, highlighted by steady new customer growth, a 12% increase in ARPU due to mid-market success, and accelerated expansion following the launch of its B2C CRM.
Klaviyo Inc. (NYSE:KVYO) provides a cloud-based software-as-a-service platform in the US, the rest of the Americas, the Asia-Pacific, the UK, the rest of Europe, the Middle East, and Africa.
5. DraftKings Inc. (NASDAQ:DKNG)
Number of Hedge Fund Holders: 68
DraftKings Inc. (NASDAQ:DKNG) is one of the best growth stocks to buy for the next 20 years. On February 17, Needham lowered its price target on DraftKings to $35 from $52 with a Buy rating following a Q4 2025 earnings miss and a reduced revenue outlook for fiscal year 2026. While the firm expects the upcoming investor day to be beneficial, the analyst argued that the company must develop a prediction market product on par with Kalshi to drive meaningful revenue and cash flow.
Northland analyst Greg Gibas lowered the firm’s price target on DraftKings on the same day to $24 from $30 and maintained a Market Perform rating. The adjustment reflects a significant downward revision to the company’s 2026 guidance, which accounts for increased spending on prediction market initiatives and new jurisdiction launches. Gibas noted that the softer outlook appears to incorporate a higher degree of management conservatism as the company navigates these heavy investment cycles.
TD Cowen analyst Lance Vitanza also lowered the firm’s price target on DraftKings Inc. (NASDAQ:DKNG) to $30 from $45 with a Buy rating. The firm noted that despite Q4 performance that exceeded expectations, the stock faced a significant sell-off due to a disappointing 2026 outlook.
DraftKings Inc. (NASDAQ:DKNG) operates as a digital sports entertainment and gaming company in the United States and internationally.
4. Fair Isaac Corporation (NYSE:FICO)
Number of Hedge Fund Holders: 72
Fair Isaac Corporation (NYSE:FICO) is one of the best growth stocks to buy for the next 20 years. On February 17, Bank of America analyst Curtis Nagle reinstated coverage of FICO with a Buy rating and a $1,900 price target, highlighting the company’s strong pricing power and the growth potential of its Mortgage Direct Licensing program.
This move was part of a broader reinstatement of 19 stocks within the Information and Business Services sector, for which the firm holds a generally constructive outlook. For the group as a whole, BofA projects healthy performance in 2026, with anticipated average growth rates of 7% for revenue, 12% for EPS, and 11% for free cash flow.
Earlier on February 2, Goldman Sachs analyst George Tong lowered the firm’s price target on Fair Isaac Corporation (NYSE:FICO) to $1,777 from $2,070 with a Buy rating. Despite the lower target, the firm highlighted strong FQ1 2026 results that beat expectations and reaffirmed full-year guidance, supported by 60% year-over-year growth in mortgage origination revenue. Goldman remains bullish on the company’s outlook, citing upcoming 2026 price increases, wider adoption of FICO 10T, and market leadership as drivers for anticipated EPS growth of over 20%.
Fair Isaac Corporation (NYSE:FICO) provides analytics software in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments: Scores and Software.
3. Arista Networks Inc. (NYSE:ANET)
Number of Hedge Fund Holders: 92
Arista Networks Inc. (NYSE:ANET) is one of the best growth stocks to buy for the next 20 years. On February 13, Morgan Stanley analyst Meta Marshall raised the firm’s price target on Arista Networks to $165 from $159 and maintained an Overweight rating. This sentiment was posted following the company’s significant Q4 2025 earnings beat.
The firm highlighted a $700 million increase in deferred revenue and noted that Arista held its gross margin guidance steady despite headwinds in the memory market. Additionally, Meta Marshall pointed to raised AI and growth targets for the year as key drivers for the updated valuation.
Evercore ISI analyst Amit Daryanani also raised the firm’s price target on Arista Networks Inc. (NYSE:ANET) to $200 from $175 with an Outperform rating following a robust December quarter beat. Daryanani noted that strong guidance for the March quarter and an increased 2026 revenue growth target of 25% underscore the company’s significant momentum.
Arista Networks Inc. (NYSE:ANET) develops, markets, and sells data-driven, client-to-cloud networking solutions for AI, data center, campus, and routing environments in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific.
2. Lam Research Corporation (NASDAQ:LRCX)
Number of Hedge Fund Holders: 93
Lam Research Corporation (NASDAQ:LRCX) is one of the best growth stocks to buy for the next 20 years. Earlier on January 29, TD Cowen raised its price target on Lam Research to $290 from $170 while keeping a Buy rating. The firm identified the 2026 Wafer Fabrication Equipment/WFE outlook of $135 billion as a major positive surprise, particularly when considering the current constraints in cleanroom availability.
On the same day, RBC Capital raised its price target on Lam Research to $290 from $260 and maintained an Outperform rating following strong Q4 2025 results fueled by a healthy equipment market and market share gains. While the firm noted that NAND spending remains inconsistent, it highlighted Lam’s solid progress in the Foundry sector and its ability to capitalize on strength in advanced packaging and high-bandwidth memory technologies.
Deutsche Bank also raised its price target on Lam Research Corporation (NASDAQ:LRCX) to $245 from $175 with a Buy rating following the company’s latest earnings report. The firm characterized the company’s current performance as firing on all cylinders.
Lam Research Corporation (NASDAQ:LRCX) designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits in the US, China, Korea, Taiwan, Japan, Southeast Asia, and Europe.
1. Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders: 114
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which found that using Taltz (ixekizumab) and Zepbound (tirzepatide) together provided superior results for adults with moderate-to-severe plaque psoriasis and obesity. Taltz clears skin by blocking a specific protein in the body that causes inflammation, whereas Zepbound reduces body weight by mimicking natural hormones to lower appetite and calorie intake.
At 36 weeks, 27.1% of participants using the combination achieved both complete skin clearance and at least 10% weight loss, compared to only 5.8% of those using Taltz alone. This landmark study marks Taltz as the first psoriatic biologic to show a successful comprehensive treatment approach when paired with an incretin therapy for obesity.
These findings suggest that addressing obesity simultaneously with Zepbound can directly reduce the overall burden of psoriasis, which is often harder to treat in patients with higher body weight. The safety profile for the combined treatment was consistent with the known effects of each drug, with most adverse events reported as mild to moderate. Common side effects for the combination arm included nausea, diarrhea, and injection site reactions, while the Taltz-only group frequently reported nasopharyngitis and injection site reactions.
Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets human pharmaceutical products in the US, Europe, China, Japan, and internationally.
While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
